Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 17/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1747946 | 0.88 | DGAT1 (0.69) | DGAT1NPC1RAB9A | |
| SCHEMBL1747947 | 0.88 | DGAT1 (0.69) | DGAT1NPC1RAB9A | |
| SCHEMBL1747978 | 0.83 | DGAT1 (1.00) | DGAT1DHODH | |
| SCHEMBL12429029 | 0.83 | DGAT1 (1.00) | DGAT1DHODH | |
| SCHEMBL2307191 | 0.83 | DGAT1 (0.82) | DGAT1NPC1RAB9A | |
| SCHEMBL2396211 | 0.83 | DGAT1 (0.82) | DGAT1NPC1RAB9A | |
| SCHEMBL2309473 | 0.83 | DGAT1 (0.82) | DGAT1NPC1RAB9A | |
| SCHEMBL2308477 | 0.82 | DGAT1 (0.78) | DGAT1NPC1RAB9A | |
| SCHEMBL2309570 | 0.82 | DGAT1 (0.78) | DGAT1NPC1RAB9A | |
| SCHEMBL1748121 | 0.82 | DGAT1 (0.58) | DGAT1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | DGAT1 34/4885NPC1 187/4885RAB9A 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.